Search - tctmd.com

Displaying 741 - 760 of 2308

Sort: Relevancy | Date

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

News Conference News TCT 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

November 03, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet

News Daily News

STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet

October 29, 2021

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

News Daily News

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

October 29, 2021

Polygenic Risk Score IDs People at Risk for Early MI, Death

News Daily News

Polygenic Risk Score IDs People at Risk for Early MI, Death

October 26, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

News Daily News

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

October 06, 2021

Device-Detected AF Directly Linked to Ischemic Strokes

News Daily News

Device-Detected AF Directly Linked to Ischemic Strokes

October 04, 2021

COVID-19: TCTMD’s Dispatch for October Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 1

October 04, 2021

TAVI Is Broadening the Treatable AS Population, Not Cutting Into SAVR

News Daily News

TAVI Is Broadening the Treatable AS Population, Not Cutting Into SAVR

September 30, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

FDA Investigating Possible Sex Differences in LAAO Outcomes

News Daily News

FDA Investigating Possible Sex Differences in LAAO Outcomes

September 27, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.